Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright
HC Wainwright has reissued a "Neutral" rating for Summit Therapeutics (NASDAQ:SMMT), aligning with the analyst consensus of "Hold" and an average target price of $24.25. The company's shares are trading near their 52-week low at $12.63, and it reported a quarterly EPS of ($0.28), slightly below estimates. Notably, corporate insiders have significantly increased their holdings, purchasing 7.87 million shares valued at approximately $103.6 million in the last 90 days.
Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why
Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss of $0.28 per share. Despite the stock's decline, company insiders have shown strong confidence, purchasing 7.87 million shares worth about $103.6 million in the last quarter, bringing their collective ownership to 83.5%.
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT
Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past three months. The company's stock opened down 7.3% at $14.00, and analysts currently have a consensus "Hold" rating with a target price of $24.25, following a missed EPS estimate.
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside
Summit Therapeutics Inc.'s average 12-month price target has been lowered to $28.34 from $29.52 by 14 analysts, yet this new target still suggests an 88% upside from its Aug. 11 closing price. The consensus rating for the stock remains a "Buy" among 18 analysts.
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab
Summit Therapeutics (SMMT) shares rose after China's National Medical Products Administration approved a label expansion for its bispecific antibody ivonescimab, allowing its first-line use with chemotherapy for advanced squamous non-small cell lung cancer. Despite an extremely high price-to-sales ratio and ongoing losses, insider purchases totaling $103.6 million signal strong confidence from those closest to the company. The company's GF Score™ is a low 27/100, reflecting significant challenges in profitability and growth, even with moderate financial strength.
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
Summit Therapeutics announced that its partner Akeso has received approval in China for ivonescimab for use in squamous non-small cell lung cancer (NSCLC). This approval marks a significant milestone for the bispecific antibody, which combines immunotherapy and anti-angiogenesis effects. Ivonescimab is also being developed by Summit Therapeutics in multiple Phase III clinical trials for NSCLC and other solid tumor settings.
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners
Leerink Partners upgraded Summit Therapeutics (NASDAQ:SMMT) from "underperform" to "market perform" with a $13 price target. The company currently holds an average "Hold" rating from analysts with an average price target of $24.25, and recently reported quarterly EPS of -$0.28, missing estimates. Insider buying activity has been significant, with the CEO and CFO purchasing large quantities of shares, leading to insiders owning 83.5% of the company.
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?
Summit Therapeutics (SMMT) has initiated a new Phase II/III trial (HARMONi-GU1) for its drug ivonescimab in first-line bladder cancer, broadening its potential applications beyond lung cancer. While this reinforces the drug's long-term multi-tumor ambition, the near-term investment focus remains on the FDA's decision for ivonescimab in EGFR-mutant NSCLC, expected by November 14, 2026. The trial adds to the company's R&D spending while Summit remains loss-making.
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?
Summit Therapeutics (SMMT) has broadened its ivonescimab program by initiating a Phase II/III trial for first-line bladder cancer, adding to its growing list of target tumors. While this reinforces the long-term potential of ivonescimab, the near-term investment focus remains on the FDA's decision for EGFR-mutant NSCLC, with a PDUFA date of November 14, 2026. The company remains loss-making, and analysts express caution regarding increased R&D spending and the need for clear differentiation to achieve commercial success.
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics
H.C. Wainwright has reiterated a Neutral rating on Summit Therapeutics (NASDAQ:SMMT), noting the company's stock has declined significantly over the past year. The firm highlighted Merck & Co.'s strategy for KEYTRUDA, which impacts the competitive landscape for Summit's drug candidate, ivonescimab. Upcoming catalysts for Summit include HARMONi-3 trial results and a PDUFA date in late 2026.
Summit expands ivonescimab's challenge to Keytruda into bladder cancer
Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims to establish ivonescimab, a PD-1/VEGF bispecific antibody, in additional PD-1-dominated oncology indications, leveraging its mechanism that targets immune evasion and angiogenesis.
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration. Despite significant R&D spending and no current revenue, the drug's broad clinical activity across multiple tumor types suggests strong future revenue potential, although key risks such as trial failures remain.
Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer
Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, aiming to generate registrational data for ivonescimab's application in new tumor types, building on promising earlier results in colorectal cancer.
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study
Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, aiming to enroll approximately 800 patients. The study expands ivonescimab's development program, which now includes 16 Phase III clinical trials across various tumor types, complementing a Biologics License Application for NSCLC with an FDA PDUFA goal date of November 14, 2026.
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Summit Therapeutics has announced the expansion of its ivonescimab global development program with the initiation of the Phase II/III HARMONi-GU1 study for first-line bladder cancer. This trial will evaluate ivonescimab alongside enfortumab vedotin against the current standard of care, pembrolizumab plus enfortumab vedotin, in patients with previously untreated locally advanced or metastatic urothelial carcinoma. This adds to the existing 15 Phase III ivonescimab studies across various tumor types, aiming to address significant unmet needs in bladder cancer treatment.
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside
Summit Therapeutics Inc. (SMMT) presents a compelling opportunity in the biotechnology sector, with analysts projecting a potential upside of 117.69% based on an average target price of $28.34. The company, focused on innovative biopharmaceuticals like ivonescimab for cancer treatment, is currently in phase III clinical trials. Despite facing financial challenges common to biopharmaceutical companies at this stage, technical indicators suggest the stock may be oversold, potentially offering a buying opportunity for risk-tolerant investors interested in long-term growth.
Lightning Round: Summit Therapeutics is a great spec, says Jim Cramer
Jim Cramer, host of "Mad Money," offered his insights on several stocks during a Lightning Round segment. He specifically highlighted
SMMT|Summit Therapeutics Inc|Price:13.030|Chg%:-0.410
This article provides a comprehensive stock analysis of Summit Therapeutics Inc (SMMT) from TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fairly valued stock, despite recent weak market performance. The analysis also details analyst ratings, institutional ownership, and key strengths like high profit growth and its lead development candidate, ivonescimab.
Summit Therapeutics upgraded to Hold as FDA reviews ivonescimab approval, decision expected by Nov 2026.
Summit Therapeutics has been upgraded from Sell to Hold due to the FDA's ongoing review of ivonescimab, with a decision anticipated by November 14, 2026. While the HARMONI study showed statistically significant progression-free survival, overall survival only presented a favorable trend. The company faces stiff competition in the PD-1 therapy market, and investors are awaiting further data and clarity on its competitive standing.
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed?
Summit Therapeutics experienced a 13.2% stock drop following various updates, including a smaller net loss in Q2 2026, a US$380 million equity offering, and crucial overall survival data from its Phase III HARMONi trial for ivonescimab. The company also announced a new collaboration with Arcus Biosciences for a kidney cancer trial. These developments, particularly the encouraging HARMONi data, reinforce ivonescimab's central role in Summit's strategy, though regulatory approval risk remains significant.
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed?
Summit Therapeutics (SMMT) recently announced a reduced net loss, a US$380 million equity offering, and updated overall survival data from its HARMONi trial for ivonescimab, alongside a new kidney cancer trial collaboration. The updated HARMONi data and expanded clinical focus reinforce ivonescimab's central role in Summit's strategy, despite regulatory risks associated with FDA approval and the need for significant revenue and earnings growth to meet analyst projections. The article explores how these developments impact the investment narrative, particularly concerning the upcoming PDUFA decision for ivonescimab.
Summit Therapeutics Inc (SMMT) Institutional Confidence
Summit Therapeutics Inc (SMMT) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 11.68% quarter-over-quarter, now standing at 15.81%. Steven Cohen is the largest institutional shareholder, holding 856.57K shares, despite a slight decrease in his holdings.
Summit Therapeutics stock hits 52-week low at 12.52 USD
Summit Therapeutics stock has fallen to a 52-week low of $12.52, down nearly 60% from its high, with analysts revising earnings estimates downward. Despite this, an InvestingPro analysis suggests the stock may be undervalued. The company recently reported a significant net loss and mixed analyst ratings, with some maintaining a Buy rating while others lowered price targets due to trial timing concerns.
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab
Summit Therapeutics announced its Q2 2026 financial results and significant clinical advancements for ivonescimab. Key highlights include consistent overall survival in both Western and Asian patients for EGFRm NSCLC post-TKI, and a statistically significant overall survival benefit for ivonescimab plus chemotherapy in 1L Squamous NSCLC from the HARMONi-6 trial conducted in China. The company also reported closing the quarter with $690.7 million in cash and investments.
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com
Summit Therapeutics (SMMT) stock has dropped to a 52-week low of $12.52, down nearly 60% from its high, with analysts revising earnings estimates downward. Despite this, InvestingPro suggests the stock may be undervalued. The company recently reported a Q2 net loss of $216 million, missing analyst expectations, while analysts reiterated Overweight/Buy ratings but lowered price targets due to concerns about the HARMONi-3 trial timing.
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) related to alleged self-dealing. The firm is encouraging long-term SMMT stockholders to contact them for a free consultation as they may be entitled to damages and corporate governance reforms. Kuehn Law covers all case costs and does not charge its investor clients.
Summit Therapeutics officers investigated for possible shareholder duty breaches and self-dealing.
Kuehn Law, PLLC is investigating officers and directors of Summit Therapeutics Inc. for potential breaches of fiduciary duties and self-dealing, which could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to seek a free consultation to explore their rights. This investigation raises concerns about management integrity and investor protection at Summit Therapeutics.
Summit Therapeutics (SMMT) Updates Ivonescimab Progress, Is The 52% Undervalued View Convincing?
Summit Therapeutics (SMMT) has presented updated Phase III data for ivonescimab, a new PDUFA date, and a collaboration with Arcus Biosciences, yet its share price has declined in the short term. While a popular narrative suggests the company is 52% undervalued based on future cash flows from its broad pipeline, its current P/B ratio of 17.3x implies a rich valuation compared to industry peers. The article explores the tension between these valuation perspectives and highlights risks such as trial failures or dilutive funding.
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.67, ranking 277 out of 386 in its industry, with an average price target of $34.50, suggesting a significant upside. Analysts project the company's next quarter revenue to be $90.91 million and anticipate EPS of -$0.28, following a previous quarter's EPS of -$0.24. The consensus amongst 18 analysts is a "Buy" rating for SMMT stock.
What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health
Summit Therapeutics (SMMT) reported a Q4 2025 non-GAAP EPS miss, highlighting its status as a pre-revenue clinical-stage biotechnology firm with substantial cash burn. Despite the miss, the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab in NSCLC, with a PDUFA date of November 14, 2026, is a key catalyst. The company maintains a strong cash reserve of $713.4 million, providing a runway for its extensive Phase III pipeline, but future dilution remains a risk for investors as it navigates the path to commercialization.
Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept
Jefferies has lowered its price target for Summit Therapeutics (SMMT) shares to $15 from a previous $17, while reiterating a Hold rating on the stock. This adjustment reflects an updated valuation by the analyst firm, indicating a revised outlook for the company's future performance or market conditions.
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside
Summit Therapeutics Inc.'s average 12-month stock price target has been adjusted to $29.06, down from $29.84, based on estimates from 14 analysts. This new target suggests a potential upside of approximately 94% from its closing price on July 23. The consensus rating for SMMT remains a "Buy" among 17 analysts.
Summit Therapeutics (NASDAQ: SMMT) advances ivonescimab, holds $690.7M cash
Summit Therapeutics reported its Q2 2026 financial results, including a GAAP net loss of $215.7 million and non-GAAP net loss of $147.0 million. The company holds $690.7 million in cash and short-term investments and is actively advancing its lead asset, ivonescimab, a bispecific antibody for cancer treatment. Key developments include consistent overall survival data for ivonescimab in NSCLC patients and significant progress in its clinical trial programs, including a BLA action date of November 14, 2026, for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC.
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics has disclosed a "going concern" risk due to insufficient cash and short-term investments to fund its operations for the next year. The company, despite raising $299.2 million through its ATM facility, expects continued operating losses and is exploring financing options. Summit Therapeutics also recently sold its ridinilazole asset for an upfront payment and potential future milestones and royalties.
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
Summit Therapeutics announced its financial results for Q2 and H1 2026, highlighting significant progress in the clinical development of ivonescimab, a bispecific antibody for cancer treatment. The company reported consistent overall survival data for ivonescimab in NSCLC patients across Western and Asian populations, with a BLA accepted by the FDA for ivonescimab in EGFRm NSCLC with a PDUFA date of November 14, 2026. Summit closed the second quarter with strong financial liquidity, with $690.7 million in cash and investments.
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
Summit Therapeutics announced updated overall survival data from its Phase 3 HARMONi study for its lead cancer drug, ivonescimab, for specific forms of lung cancer. Extended follow-up data shows stronger survival advantages for patients, particularly Western participants, with a consistent safety profile. The company has submitted these findings to the FDA to support its Biologics License Application, with a target action date of November 14, 2026.
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ...
Summit Therapeutics Inc (SMMT) reported a strong cash position of $690.7 million in Q2 2026 and positive clinical data for its lead asset, Ivanizumab, with collaborations and a broad trial pipeline. However, operating expenses increased, and Ivanizumab still needs statistically significant overall survival benefits for some FDA approvals, facing potential delays and competition. The earnings call also addressed questions regarding trial timelines, competitive positioning, and the translatability of results to larger markets.
Summit Therapeutics (SMMT) sets up $380M at-the-market share offering
Summit Therapeutics (SMMT) has established an at-the-market (ATM) equity program to offer and sell up to $380 million of common stock through J.P. Morgan Securities LLC. The proceeds are primarily intended to fund the development of its lead oncology candidate, ivonescimab, for various cancer trials, and for general working capital. The company disclosed substantial doubt about its ability to continue as a going concern without additional capital, as existing cash and investments are insufficient to cover 12 months of planned operations.
Summit Therapeutics (NASDAQ: SMMT) posts loss, eyes FDA decision
Summit Therapeutics reported a net loss of $215,700 for the quarter and $405,124 for the six months ended June 30, 2026, and acknowledged that its current liquidity is insufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. The company's strategy focuses on its bispecific antibody, ivonescimab, which is undergoing multiple Phase III trials, with a Biologics License Application accepted by the FDA for EGFR-mutated NSCLC, though the FDA has stated a statistically significant overall survival benefit is expected for approval. Summit is actively pursuing additional financing through various means including equity and debt offerings, collaborations, and licensing arrangements to support its ongoing research and development efforts and address its capital needs.
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides details on Summit Therapeutics Inc. (SMMT), including its latest stock price ($13.58, up 9.35%), market capitalization ($11.63B), and recent news. Key updates include strong lung cancer survival results reported by Summit and its financial results for Q2 2026. The article also lists other trending stocks and general market sentiment.
Summit Therapeutics (SMMT) Q2 2026 earnings summary
Summit Therapeutics reported its Q2 2026 earnings, highlighting the significant progress of its drug Ivonescimab, a PD-1/VEGF bispecific antibody, which has shown strong efficacy in Phase III trials and is awaiting FDA approval. The company announced $690.7 million in cash and short-term investments but indicated that additional capital may be needed within the next 12 months to fund operations. Preparations for Ivonescimab's commercial launch are underway, with a PDUFA date set for November 14, 2026.
Summit Therapeutics says cash crunch could impact its ability to continue
Summit Therapeutics (SMMT) announced that its current cash reserves are insufficient to fund operations for at least the next year, leading to a ~5% drop in shares during after-hours trading. The company's cash crunch raises concerns about its ability to continue operations.
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics
H.C. Wainwright has reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ:SMMT) with no 12-month price target. The firm noted Summit's disclosure of a third HARMONi OS analysis, which reduces concerns about the global survival benefit of ivonescimab and supports its pending BLA. Despite this, H.C. Wainwright stated that further trials are needed to establish ivonescimab's commercial viability beyond the post-EGFR-TKI setting.
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
Summit Therapeutics announced that extended follow-up data from its HARMONi study for the lead cancer drug, ivonescimab, shows stronger survival advantages in patients with EGFR-mutated non-small cell lung cancer. The latest analysis demonstrated an improved hazard ratio for overall survival, aligning with results from Asian patients, and maintained a consistent safety profile. These findings have been submitted to the FDA for its Biologics License Application, with a target action date of November 14, 2026.
Summit: Updated HARMONi OS Analysis Shows HR 0.76 for Ivonescimab Across Global Population
Summit Therapeutics reported updated HARMONi overall survival results for ivonescimab, showing a hazard ratio of 0.76 in both the full population and the western subgroup. The updated analysis, with a data cutoff of June 2026, also noted an acceptable safety profile, with detailed data shared with the FDA and planned for an upcoming medical conference before the BLA PDUFA date of November 14, 2026. This consistency builds on prior Asian results and enhanced western subgroup data with increased follow-up.
Summit Therapeutics stock rises on positive cancer trial data
Summit Therapeutics' stock rose 3% following positive updated overall survival results from its Phase III HARMONi clinical trial for ivonescimab in
Summit Therapeutics (SMMT) Is Down 5.4% After Out-Licensing Ridinilazole To Biossil Inc.
Summit Therapeutics (SMMT) has out-licensed its Phase III antibiotic, ridinilazole, to Biossil Inc. for an upfront payment of US$500,000 and potential milestones up to US$104.5 million. This move is strategic, allowing Summit to focus on its oncology programs, particularly ivonescimab, and monetize a non-core asset. While the deal is not expected to significantly alter near-term financial catalysts, it reinforces management's commitment to ivonescimab as the core value driver and provides some non-dilutive funding potential.
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a Potential 108.75% Upside in Biotech
Summit Therapeutics Inc. (SMMT) is a biopharmaceutical company focusing on groundbreaking therapies for conditions like non-small lung cancer and colorectal cancer, with its flagship product ivonescimab in Phase III trials. Analysts project a potential upside of 108.75% from its current stock price, despite the company's high R&D costs and unproven revenue streams, reflected in its negative forward P/E ratio. The stock's future performance is heavily reliant on the success of its clinical trials and subsequent commercialization, making it a high-risk, high-reward investment in the biotech sector.
Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale
Summit Therapeutics (SMMT; SUMM) has divested its investigational Phase 3 antibiotic, ridinilazole, to Biossil for up to US$104.5 million in milestones, signaling a strategic shift to focus entirely on its oncology drug, ivonescimab. This move comes as the company aims to capitalize on the growing market demand for cancer treatments, despite increasing costs and market competition. Summit anticipates releasing interim data and filing a Biologics License Application (BLA) for ivonescimab in the second half of 2026.
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call on Thursday, July 23, 2026, at 4:30 p.m. EDT to discuss its second-quarter 2026 financial results and operational progress. The biopharmaceutical oncology company, focused on developing medicinal therapies, will provide access to the live and archived webcast through the investor information section of its website.
